In patients with IDH-mutant glioma, where disease stability is the primary goal and tumor shrinkage is not typically expected with treatment, disease control rate (DCR; best response rate of stable disease or better) is a reasonable outcome measure in place of overall response rates (ORR). This evidence concerns the gene IDH2 and neoplasm.